ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 02 Jul 2018
Last Updated on 01 Apr 2020
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Alfuzosin 10 mg tablet and dutasteride 0.5 mg capsule for treating benign prostatic hyperplasia

Subsidy status

Alfuzosin 10 mg tablet and dutasteride 0.5 mg capsule are recommended for inclusion on the MOH Standard Drug List (SDL).

SDL subsidy does not apply to tamsulosin 0.4 mg tablet or dutasteride 0.5 mg/tamsulosin 0.4 mg capsule.


Treatments for benign prostatic hyperplasia (1 Apr 2020)